PX1 Research supplies laboratory-grade PNC-27 peptide engineered specifically for rigorous in vitro and preclinical oncology research. Every batch is manufactured in USA-based, GMP-compliant facilities and thoroughly verified via RP-HPLC, tandem mass spectrometry, and endotoxin assays. Researchers seeking reliable, batch-traceable compounds can access certified PNC-27 with lot-specific certificates of analysis.
PX1 Research supplies laboratory-grade PNC-27 peptide engineered specifically for rigorous in vitro and preclinical oncology research. Every batch is manufactured in USA-based, GMP-compliant facilities and thoroughly verified via RP-HPLC, tandem mass spectrometry, and endotoxin assays. Researchers seeking reliable, batch-traceable compounds can access certified PNC-27 with lot-specific certificates of analysis.
When evaluating a supplier with PNC-27 peptide for sale, scientific institutions require verifiable analytical data rather than unbacked purity assertions. PNC-27 is a specialized membrane-active research peptide derived from the p53 sequence attached to a transmembrane-penetrating domain. Its synthetic stability and structural integrity depend heavily on accurate solid-phase peptide synthesis (SPPS) and rigorous post-synthesis purification.
Investigators can buy PNC-27 peptide for sale directly through PX1 Research, where each lot undergoes comprehensive testing at an independent ISO 17025 accredited laboratory. Our commitment to batch traceability ensures that your research models maintain consistent, repeatable outcomes across all experimental runs. Explore our full catalog of all research peptides to support your ongoing cellular and molecular assays.
PNC-27 is a 32-residue synthetic peptide constructed by fusing two distinct functional domains: an HDM-2 binding domain derived from the p53 protein (residues 12–26) and a cell-penetrating peptide (CPP) domain derived from the antennapedia homeodomain residue sequence (penetratin). The resulting primary amino acid sequence enables the peptide to interact selectively with specific membrane targets while traversing biological barriers in vitro.
Preclinical structural analyses indicate that the alpha-helical conformation of the p53-derived section is crucial for high-affinity binding to its primary molecular target, HDM-2 (human double minute 2 protein, also known as MDM2). In laboratory settings, maintaining the spatial integrity of this helical motif requires precise lyophilization protocols and strict temperature control during storage and transit. Details on proper storage parameters can be found in our peptide research library.
The primary mechanism of PNC-27 centers on its capacity to target membrane-bound HDM-2 expressed on transformed or cancerous cell lines. While HDM-2 is historically recognized as an intranuclear E3 ubiquitin ligase that regulates p53 degradation, preclinical studies have demonstrated that overexpressing transformed cells frequently display HDM-2 directly on their outer plasma membrane.
Upon binding to membrane-localized HDM-2, PNC-27 undergoes a conformational transition that leads to membrane insertion. In vitro fluorescence and electron microscopy assays indicate that the peptide oligomerizes within the lipid bilayer, creating distinct transmembrane pores. This physical disruption disrupts osmotic equilibrium, leading to rapid cellular swelling, plasma membrane rupture, and non-apoptotic cell death (necrosis).
A critical feature of PNC-27 observed in preclinical assays is its ability to induce cell lysis independently of functional p53 expression. Many human cancer cell lines harbor mutated or non-functional p53 genes, rendering classical pro-apoptotic compounds ineffective. Because PNC-27 utilizes HDM-2 merely as a membrane anchor to facilitate pore formation rather than activating p53-dependent transcriptional pathways, its activity remains robust across both p53-wildtype and p53-mutant/null cell lines.
In vitro comparative assays show that incubation with PNC-27 leads to a rapid release of lactate dehydrogenase (LDH)—a classical hallmark of necrotic membrane rupture—within 30 to 60 minutes of application. This rapid temporal response distinguishes PNC-27 from traditional cytotoxic compounds that require several hours or days to initiate caspase cascades.
A major area of investigation involving PNC-27 is its high selectivity for transformed cell membranes compared to non-transformed control cells. In vitro studies evaluated across various cell lines (including pancreatic carcinoma, breast adenocarcinoma, and leukemia models) indicate that untransformed mononuclear cells, fibroblasts, and endothelial cells lack significant levels of surface-localized HDM-2.
Consequently, when non-transformed cell cultures are exposed to PNC-27 at equivalent experimental concentrations, the peptide fails to bind to the outer lipid bilayer and does not induce pore formation or cytotoxicity. Researchers investigating cell surface dynamics utilize PNC-27 to probe the topological distribution of HDM-2 and assess the physical parameters governing membrane-selective peptide toxicity.
Within the domain of membrane-active and pro-apoptotic research peptides, PNC-27 is often evaluated alongside structurally or functionally related compounds. For instance, PNC-28 represents another p53-derived peptide featuring a identical HDM-2 binding region but altered flanking sequences, exhibiting similar membrane-disruptive behavior in rodent tumor models.
In contrast, compounds like FOXO4-DRI operate via completely different pathways; FOXO4-DRI targets senescent cells by disrupting the FOXO4-p53 interaction to induce classical caspase-dependent apoptosis rather than rapid membrane necrosis. Furthermore, investigators studying cellular signaling and tissue repair mechanisms often contrast these cytotoxic peptides with broad-spectrum cytoprotective agents such as BPC-157 in baseline cell viability assays. Understanding these mechanistic differences is essential when designing multi-compound comparative research protocols.
PNC-27 is supplied as a sterile, lyophilized cake to ensure long-term peptide stability. To reconstitute the compound for in vitro experimentation, researchers should follow established laboratory protocols using Bacteriostatic Water or sterile 0.9% Sodium Chloride injection solution.
Gently introduce the diluent along the inner glass wall of the vial to avoid agitating the peptide solution. Allow the lyophilizate to dissolve naturally without violent vortexing, which can introduce shear forces that alter tertiary folding. For detailed guidelines on solvent selection, concentration calculations, and storage aliquoting, consult our comprehensive reconstitution guide. Reconstituted solutions should be stored at -20°C or -80°C to prevent degradation over extended experimental schedules.
To ensure experimental reproducibility, every lot of PNC-27 offered by PX1 Research undergoes strict analytical testing. High-Performance Liquid Chromatography (RP-HPLC) verifies that the peptide achieves a chemical purity of >98%, minimizing the presence of truncated sequence impurities or synthesis side-products that could skew biological assays.
Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weight of the 32-amino-acid peptide against its theoretical mass. Additionally, all lots undergo Chromogenic LAL testing to verify that bacterial endotoxin levels remain strictly below <0.01 EU/mg. This zero-compromise quality standard prevents endotoxin-induced background signals in delicate cell culture assays. Institutions requiring high-volume supplies for ongoing studies can establish wholesale lab accounts for streamlined batch scheduling.
PX1 Research stands out as a premier American vendor for high-purity research compounds. All our peptides are manufactured within USA-based, ISO-certified, and GMP-compliant facilities. We eliminate the uncertainties associated with overseas suppliers by maintaining direct, transparent supply chains with complete lot traceability.
Orders placed Monday through Friday ship same-day from our strategically located distribution hubs in California and Arizona. Each shipment includes secure temperature-controlled packaging options and direct access to downloadable, lot-specific Certificates of Analysis (COAs), ensuring your research laboratory receives identical, highly pure reagents every time.
What is PNC-27 and how is it used in laboratory research?
PNC-27 is a synthetic 32-residue research peptide comprising a p53-derived HDM-2 binding domain linked to a transmembrane penetratin sequence. In preclinical and in vitro laboratory research, it is studied for its ability to bind membrane-bound HDM-2 on transformed cells and induce non-apoptotic cell lysis via pore formation.
How does PNC-27 induce cell lysis in cancer cell models?
Preclinical studies show that PNC-27 binds selectively to HDM-2 expressed on the outer plasma membrane of cancer cells. Upon binding, the peptide inserts into the lipid bilayer, oligomerizes into transmembrane pores, disrupts cellular osmoregulation, and leads to rapid cell necrosis.
Does PNC-27 require a functional p53 gene to work in vitro?
No. PNC-27 operates independently of the p53 pathway. It uses the HDM-2 protein solely as a cell-surface target for membrane insertion and lysis, making it effective in preclinical models targeting both p53-wildtype and p53-mutant/deficient cell lines.
What purity levels are guaranteed for PX1 Research PNC-27?
PX1 Research guarantees that every lot of PNC-27 meets or exceeds >98% purity as measured by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and confirmed by Mass Spectrometry (MS).
How is endotoxin testing performed on PNC-27 lots?
Every batch undergoes rigorous Limulus Amebocyte Lysate (LAL) chromogenic assay testing to ensure endotoxin levels remain below <0.01 EU/mg, preventing cell culture contamination or unwanted inflammatory responses in research models.
What is the recommended storage procedure for lyophilized PNC-27?
Lyophilized PNC-27 should be stored in a dry, dark environment at -20°C or -80°C upon receipt. Under these conditions, the peptide remains stable for up to 24 months. Avoid repeated freeze-thaw cycles after reconstitution.
How does PNC-27 differ from PNC-28?
Both PNC-27 and PNC-28 are p53-derived peptides targeting HDM-2. However, PNC-28 features a slightly altered primary sequence length and flanking structural modifications. Both act as membrane-active necrotic agents in preclinical studies.
Where does PX1 Research ship PNC-27 from?
All PX1 Research compounds are manufactured in the USA and shipped directly from our primary distribution centers located in California and Arizona, with same-day dispatch for orders confirmed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.